InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: corporalagarn post# 200190

Thursday, 12/18/2014 1:26:48 PM

Thursday, December 18, 2014 1:26:48 PM

Post# of 345789

I'm absolutely shocked people are taking King at his word.



King and company accomplished something no small biotech has ever done before. Phase III "Sunrise" FDA approvall with 2 peeks all based on combination data that shows the strength of PS Targeting is much stronger than previously though, combined with FDA awarded Fast Track and $63 Million on the books...

Peregrines checkmate is the quietest you'll ever hear of and Millions of more dollars rolling Bavis way is what I believe

Checkmate mate : )

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News